Article and Video CATEGORIES

Cancer Journey

Search By

Lyudmila A. Bazhenova, MD, is a board-certified medical oncologist. Her clinical practice is devoted to patients with all types of lung cancer, and she has particular expertise with female patients and nonsmokers. She believes in a multidisciplinary approach to lung cancer, and works closely with surgical oncologists and radiation oncologists to provide the best patient experience.

She leads a weekly "lung tumor board," where expert physicians and scientists from several specialties review cases to develop the best possible individualized treatment plan.

Lung Cancer Onctalk 2023 - Dr. Lyudmila Bazhenova
A recorded live event where a team of top oncologists discusses emerging concepts and best practices in non-small cell lung cancer (NSCLC).
Author
Lyudmila Bazhenova MD - Guest Faculty
Image
Lung Cancer OncTalk 2023

At our live event, Lung Cancer OncTalk 2023, Lyudmila Bazhenova talks about Antibody Drug Conjugates, Toxicities in Antibody Drug Conjugate Treatment, and Bispecific Antibodies in Lung Cancer. 

To watch the complete playlist click here.

Video Language

Next Previous link

Previous PostNext Post

Related Content

Article
Las biopsias líquidas están revolucionando la forma en que combatimos el cáncer, ofreciendo un futuro donde la detección y el tratamiento son más rápidos, precisos y menos invasivos.
Image
Videoteca de Cáncer de Pulmon - 2025
Video
Como parte de la Videoteca de Cáncer de Pulmón en Español 2025, oncólogos expertos discuten las opciones de tratamiento y la información más emergente en cáncer de pulmón. El Dr. Raez aborda la terapia para cánceres de pulmón EGFR y ALK, además de analizar otros tres temas de actualidad. La Dra. Viola y la Dra. Riaño también contribuyen a esta videoteca, cada una presentando tres temas relevantes sobre el cáncer de pulmón.
Article
The journey to conquer lung cancer is paved with scientific discovery, and the identification of the EGFR and ALK genes as crucial players marks a significant milestone. Unraveling how mutations in these seemingly small segments of our DNA can unleash the destructive force of cancer has opened up exciting new therapeutic avenues. This exploration delves into the cutting-edge world of EGFR and ALK-targeted therapies, highlighting the progress made and the ongoing quest for even more effective and personalized strategies to combat this formidable disease.